Lexaria Bioscience Corp (LXX.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 08/31
| 02-2025 | 11-2024 | 08-2024 | 05-2024 | 02-2024 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 2 | 33 | -8 | 39 | 16 |
| Accounts receivable | -68 | -109 | 46 | 125 | 187 |
| Other Working Capital | 1,032 | -168 | 174 | 76 | -9 |
| Other Operating Activity | -2,464 | -2,482 | -2,104 | -1,506 | -813 |
| Operating Cash Flow | $-1,498 | $-2,726 | $-1,892 | $-1,266 | $-620 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 0 | -25 | -43 | 0 | 0 |
| Purchase Sale Intangibles | -28 | -13 | -27 | -22 | -57 |
| Other Investing Activity | -28 | -13 | -27 | 0 | -57 |
| Investing Cash Flow | $-28 | $-38 | $-70 | $-22 | $-57 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 12 | 4,345 | 0 | 0 | 2,961 |
| Other Financing Activity | 0 | 0 | 0 | 5,043 | 492 |
| Financing Cash Flow | $12 | $4,345 | $0 | $5,043 | $3,453 |
| Exchange Rate Effect | -95 | -3 | 2 | -1 | -25 |
| Beginning Cash Position | 8,078 | 6,500 | 8,459 | 4,705 | 1,954 |
| End Cash Position | 6,469 | 8,078 | 6,500 | 8,459 | 4,705 |
| Net Cash Flow | $-1,514 | $1,582 | $-1,961 | $3,755 | $2,776 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,498 | -2,726 | -1,892 | -1,266 | -620 |
| Capital Expenditure | -28 | -38 | -70 | -22 | -57 |
| Free Cash Flow | -1,526 | -2,764 | -1,961 | -1,288 | -677 |